Inhibiting SARS-CoV-2 viral entry by targeting spike:ACE2 interaction with O -modified quercetin derivatives
Reuben James Z. Rosal, Monissa C. Paderes · RSC Medicinal Chemistry · 2024
= 3.28 μM)). Moreover, these compounds exhibited low hepato-, nephro-, and cardiotoxicity, and their SwissADME profiles indicated favorable physicochemical, pharmacokinetic, and drug-like properties, suggesting their potential as promising lead SARS-CoV-2 S:ACE2 inhibitors.